MDLN ALERT: HBSS Probes Medline (MDLN) After Reports Reveal Undisclosed Manufacturing Violations and Failed Contamination Investigations

National shareholder rights firm Hagens Berman Sobol Shapiro (HBSS) has launched an investigation into Medline Inc. (NASDAQ: MDLN ) focusing on whether the company may have misled investors regarding the adequacy of its manufacturing quality controls and compliance with FDA safety standards.

The firm is looking into whether Medline concealed systemic lapses in its contamination protocols—specifically failures to investigate microbial incidents and batch discrepancies—that prompted regulatory scrutiny and triggered a significant decline in the company's share price.

Medline Inc. (MDLN) Investigation: Since Medline went public in December 2025, it has assured investors that "[w]e are committed to delivering products of the highest standard, which is reflected by our robust quality team of over 2,400 employees[]" and "[t]heir expertise ensures that every product bearing the Medline brand meets both our rigorous quality standards and our customers' expectations[.]"

The effectiveness of the company's quality team first came into question on June 2, 2026, when the FDA published its May 28 warning letter addressed to CEO Boyle. The FDA recited specific CGMP violations and said "your drug products are adulterated." The FDA highlighted the following deficiencies: "Between June 2, 2023 and August 27, 2025, your firm isolated objectionable microorganisms […] from finished drug product samples on approximately nine occasions[;]" "You also recovered [the objectionable microorganisms] in at least five samples taken from your manufacturing environment since January 2025[;]" "You failed to adequately investigate and implement corrective actions and preventative actions (CAPA) to determine root causes and prevent recurrence of these repeated contamination incidents[;]" and "This issue was ..."